Adjuvant treatment of GIST: Patient selection and treatment strategies

Nature Reviews Clinical Oncology

Volumn 9, Issue 6, 2012, Pages 351-358

  Joensuu, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MASITINIB; PAZOPANIB; PLACEBO; REGORAFENIB; SUNITINIB; VATALANIB;

ABDOMINAL PAIN; ADVANCED CANCER; AMINO ACID SUBSTITUTION; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; DERMATITIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MITOSIS; MUTATIONAL ANALYSIS; NEUTROPENIA; ONCOGENE C KIT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PATIENT SELECTION; PIPERAZINES; PYRIMIDINES;

EID: 84861732669     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.74     Document Type: Review

References (82)

1. Mucciarini, C. et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 7, 230 (2007).
2. Nilsson, B. et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103, 821-829 (2005). (Pubitemid 40216412)
3. Joensuu, H. et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis based on pooled population-based cohorts. Lancet Oncol. 13, 265-274 (2012).
4. DeMatteo, R. P. et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231, 51-58 (2000). (Pubitemid 30043939)
5. Corless, C. L., Barnett, C. M. & Heinrich, M. C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 11, 865-878 (2011).
6. Andersson, J. et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am. J. Surg. Pathol. 29, 1170-1176 (2005). (Pubitemid 41232989)
7. Carney, J. A. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin. Proc. 6, 543-552 (1999).
8. Miettinen, M., Wang, Z. F. & Lasota, J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am. J. Surg. Pathol. 33, 1401-1408 (2009).
9. Novelli, M. et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 57, 259-270 (2010).
10. Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003). (Pubitemid 36159485)
11. Hirota, S. et al. Gain of function mutations of platelet-derived growth factor receptor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 125, 660-667 (2003). (Pubitemid 37070684)
12. Pacini, S. et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur. J. Hum. Genet. 16, 79-88 (2008).
13. Agram, N. P. et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 10, 853-859 (2008).
14. Woodall, C. E. et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch. Surg. 144, 670-678 (2009).
15. Emile, J. F. et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Mol. Oncol. http://dx.doi.org/10.1007/s12032-011-0074-y.
16. Casali, P. G. & Blay, J. Y. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl.), v98-v102 (2010).
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Soft tissue sarcoma. Version 1.2012 [online], http://www.nccn.org/ professionals/physician-gls/pdf/sarcoma.pdf (2012).
18. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002). (Pubitemid 34879334)
19. Blanke, C. D. et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620-625 (2008). (Pubitemid 351264357)
20. Verweij, J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364, 1127-1134 (2004). (Pubitemid 39296599)
21. Blanke, C. D. et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26, 626-632 (2008). (Pubitemid 351264358)
22. Heinrich, M. C. et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24, 4764-4774 (2006). (Pubitemid 46630941)
23. Hislop, J. et al. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J. Gastrointest. Cancer http://dx.doi.org/10.1007/s12029-011-9325-6.
24. Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338 (2006). (Pubitemid 44528723)
25. Crosby, J. A. et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann. Surg. Oncol. 8, 50-59 (2001). (Pubitemid 32140424)
26. DeMatteo, R. P. et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112, 608-615 (2008). (Pubitemid 351186201)
27. Miettinen, M., Sobin, L. H. & Lasota, J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am. J. Surg. Pathol. 29, 52-68 (2005). (Pubitemid 40023952)
28. Miettinen, M., Makhlouf, H., Sobin, L. H. & Lasota, J. Gastrointestinal stromal tumors of the jejunum and ileum. A clinopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long term follow-up. Am. J. Surg. Pathol. 30, 477-489 (2006). (Pubitemid 43740149)
29. Rutkowski, P. et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann. Surg. Oncol. 14, 2018-2027 (2007). (Pubitemid 46988258)
30. Takahashi, T. et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int. J. Clin. Oncol. 12, 369-374 (2007). (Pubitemid 47573418)
31. Tryggvason, G., Gislason, H., Magnusson, M. K. & Jonasson, J. G. Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population based incidence and pathologic risk stratification study. Int. J. Cancer 117, 289-293 (2005). (Pubitemid 41377450)
32. Steigen, S. E., Eide, T. J., Wasag, B., Lasota, J. & Miettinen, M. Mutations in gastrointestinal stromal tumors-a population-based study from Northern Norway. APMIS 115, 289-298 (2007). (Pubitemid 46743943)
33. Mazzola, P. et al. Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005. Histol. Histopathol. 23, 1379-1386 (2008).
34. Braconi, C. et al. KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann. Oncol. 19, 706-710 (2008). (Pubitemid 351461041)
35. Brabec, P. et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 56, 459-464 (2009).
36. Fletcher, C. D. et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum. Pathol. 33, 459-465 (2002). (Pubitemid 34747864)
37. Miettinen, M. & Lasota, J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23, 70-83 (2006). (Pubitemid 44692418)
38. Joensuu, H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 39, 1411.1419 (2008).
39. Gold, J. S. et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 10, 1045.1052 (2009).
40. Rossi, S. et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am. J. Surg. Pathol. 35, 1646.1656 (2011).
41. Miettinen, M. et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am. J. Surg. Pathol. 27, 625.641 (2003). (Pubitemid 36514473)
42. Miettinen, M. et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am. J. Surg. Pathol. 25, 1121.1133 (2001). (Pubitemid 32777711)
43. Rutkowski, P. et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur. J. Surg. Oncol. 37,890.896 (2011).
44. Hohenberger, P. et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br. J. Surg. 97, 1854.1859 (2010).
45. Joensuu, H. Predicting recurrence-free survival after surgery for GIST. Lancet Oncol. 10, 1025 (2009).
46. Wardelmann, E. et al. Deletion of Trp.557 and Lys.558 in the juxtamembrane domain of the c.kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int. J. Cancer 106, 887.895 (2003). (Pubitemid 37071667)
47. Martin, J. et al. Deletions affecting codons 557.558 of the c.KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J. Clin. Oncol. 23, 6190.6198 (2005).
48. DeMatteo, R. P. et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373, 1097.1104 (2009).
49. Joensuu, H. et al. One versus three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307, 1265.1272 (2012).
50. DeMatteo, R. P. et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U. S. Intergroup phase II trial ACOSOG Z9000 [abstract]. ASCO Gastrointestinal Cancers Symp. a8 (2008).
51. Kang, B. et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors [abstract]. J. Clin. Oncol. 27 (Suppl.), e21515 (2009).
52. Kanda, T. et al. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. Int. J. Clin. Oncol. http:// dx.doi.org/10.1007/s10147-011-0339-7.
53. Zhan, W. H. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a10045 (2007).
54. Nilsson, B. et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br. J. Cancer 96, 1656.1658 (2007). (Pubitemid 46847213)
55. Li, J., Gong, J. F., Wu, A. W. & Shen, L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur. J. Surg. Oncol. 37, 319.324 (2011).
56. Jiang, W..Z. et al. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J. Surg. Oncol. 104, 760.764 (2011).
57. Huang, H. et al. Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy. Med. Oncol. http://dx.doi.org/ 10.1007/s12032-011-9888-x.
58. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00103168 (2009).
59. Wang, D. et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann. Surg. Oncol. 19, 1074.1080 (2012).
60. McAuliffe, J. C. et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann. Surg. Oncol. 16, 910.919 (2009).
61. Blesius, A. et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BRF 14 trial. BMC Cancer 11, 72 (2011).
62. Hohenberger, P. et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST) [abstract]. J. Clin. Oncol. 27 (Suppl. 15), a10550 (2009).
63. Andtbacka, R. H. I. et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann. Surg. Oncol. 14, 14.24 (2007).
64. Eisenberg, B. L. & Trent, J. C. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int. J. Cancer 129, 2533.2542 (2011).
65. Reichardt, P. et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment . the first analysis in the SSGXVIII/AIO trial patient population [abstract]. Eur. J. Cancer 47 (Suppl. 2), 15 (2011).
66. Le Cesne, A. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 11, 942.949 (2010).
67. Von Mehren, M. et al. Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) [abstract]. J. Clin. Oncol. 29 (Suppl.), a10016 (2011).
68. Blesius, A. Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BRF14 prospective French Sarcoma Group randomized phase III trial. J. Clin. Oncol. 29, (Suppl.) 616s (2011).
69. Davies, H. E., Wathen, C. G. & Gleeson, F. V. The risks of radiation exposure related to diagnostic imaging and how to minimise them. BMJ 342, d947 (2011).
70. Corless C. et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001 [abstract]. J. Clin. Oncol. 28 (Suppl.), a10006 (2010).
71. Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342.4349 (2003). (Pubitemid 46621810)
72. Debiec-Rychter, M. et al. EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42, 1093.1103 (2006). (Pubitemid 44275331)
73. Miettinen, M. & Lasota, J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 130, 1466.1478 (2006). (Pubitemid 44520713)
74. Mussi, C. et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin. Cancer Res. 14, 4550.4555 (2008).
75. Bardsley, M. R. et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 139, 942.952 (2010).
76. Heinrich, M. C. Imatinib treatment of metastatic GIST: donft stop (believing). Lancet Oncol. 11, 911.912 (2010).
77. Joensuu, H. et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br. J. Cancer 104, 1686.1690 (2011).
78. Le Cesne, A. et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur. J. Cancer 46, 1344.1351 (2010).
79. Reichardt, P. et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann. Oncol. http://dx.doi.org/ 10.1093/annonc/mdr598.
80. Park, S. H. et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest. New Drugs http://dx.doi.org/10.1007/ s10637-012-9795-9.
81. George, S. et al. A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor after therapy with imatinib and sunitinib [abstract]. J. Clin. Oncol. 29 (Suppl.), a10007 (2011).
82. Demetri, G. D. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin. Oncol. 38 (Suppl. 1), S10.S19 (2011).